Press coverage about Aratana Therapeutics (NASDAQ:PETX) has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aratana Therapeutics earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.2616021869608 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Analysts Expect Aratana Therapeutics, Inc. (PETX) Will Post Quarterly Sales of $5.77 Million (americanbankingnews.com)
- Q3 2017 Earnings Estimate for Aratana Therapeutics, Inc. Issued By Jefferies Group (PETX) (americanbankingnews.com)
- Needle Action Activity Spotted in Apptio Inc (APTI) and Aratana Therapeutics Inc (PETX) – Evergreen Caller (evergreencaller.com)
- Analysts Set Expectations for Aratana Therapeutics, Inc.’s FY2021 Earnings (PETX) (americanbankingnews.com)
- -$0.27 Earnings Per Share Expected for Aratana Therapeutics, Inc. (PETX) This Quarter (americanbankingnews.com)
PETX has been the topic of a number of analyst reports. Jefferies Group LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research report on Friday, May 5th. ValuEngine lowered shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 31st. Stifel Nicolaus lowered their price objective on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. Zacks Investment Research lowered shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Finally, BidaskClub lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Aratana Therapeutics has a consensus rating of “Hold” and an average price target of $9.50.
Aratana Therapeutics (PETX) traded up 0.73% during midday trading on Friday, reaching $5.51. The company’s stock had a trading volume of 245,176 shares. The company’s market capitalization is $236.94 million. The company’s 50-day moving average price is $6.74 and its 200-day moving average price is $6.33. Aratana Therapeutics has a 1-year low of $4.97 and a 1-year high of $10.73.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. The company had revenue of $5.16 million for the quarter, compared to analyst estimates of $4.50 million. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. Aratana Therapeutics’s revenue for the quarter was down 86.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.61 EPS. On average, analysts predict that Aratana Therapeutics will post ($1.07) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Aratana Therapeutics (NASDAQ:PETX) Receives Media Sentiment Score of 0.21” was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/aratana-therapeutics-nasdaqpetx-getting-somewhat-favorable-news-coverage-report-finds-updated.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.